Inversago Pharma
in Peripheral CB1
Blockade
Full Potential of
Peripherally-acting
CB1 Inverse Agonists
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG) and Type 1 Diabetes (T1D), Prader-Willi Syndrome (PWS), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
The Peripheral CB1 Company
Targeting metabolic diseases in need of better adapted treatment options
Inversago has the know-how, technology and clinical expertise to develop safe and potent first-in-class inverse agonists of peripheral CB1 receptors to address a broad range of medical indications (conditions related to obesity such as diabetes (diabetic kidney disease (DKD), hypertriglyceridemia (HTG) and type 1 diabetes)), liver diseases (NASH), Prader-Willi Syndrome (PWS) or fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD).
INV-202, our lead program targeting metabolic disorders, is a next generation, peripherally-acting CB1 inverse agonist in clinical development. Our other candidate molecules targeting the peripheral CB1 pathway have also shown activity in several preclinical models.
Our Approach
A safe and potent CB1 inhibitor would have the potential to block or reverse (inverse agonize) the biological processes induced by supraphysiological CB1 activation and provide a novel treatment to patients.